From CAR-T and innovative drugs to precision surgery and interventional oncology, SinoHealth connects you with China's leading cancer hospitals and the newest therapies — often years ahead of Western approval.
High-volume expertise with modern chemoradiotherapy, immunotherapy and precision radiotherapy.
Some of the world's largest case experience — surgery, chemoradiation, immunotherapy and minimally invasive options.
Fudan University Shanghai Cancer Center pioneered TNBC molecular subtyping and precision treatment.
Home of satri-cel — the world's first solid-tumour CAR-T — plus advanced surgery and targeted therapy.
Leukaemia, lymphoma & myeloma — China leads in CAR-T, including BCMA-targeted CAR-T.
Ivonescimab and next-gen targeted agents for lung; ablation and TACE for liver; full colorectal care.
Approved in China (2026) for Claudin18.2+ advanced gastric cancer. No approved equivalent in the West.
A PD-1/VEGF bispecific that beat pembrolizumab head-to-head in Phase 3 lung cancer.
China developed its first original antibody-drug conjugate in 2021 and now has five-plus approved.
For blood cancers and, now, solid tumours — including next-generation therapies still in trials in the West.
Novel targeted agents, ADCs and bispecific antibodies — often available in China first.
Home-grown PD-1 checkpoint inhibitors at a fraction of Western prices.
Microwave / cryo ablation, the 'Nanoknife', TACE and iodine-125 seeds — through a needle.
Some of the world's most cost-effective carbon-ion centres, sparing healthy tissue.
High-volume robotic surgery and modern precision radiotherapy.
Send us your case for a free, confidential review and a clear plan and quote — with no obligation, in your language.
Free consultation · Reply within 24 hours · Fully confidential